Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

This study has been terminated.
(The development program has been terminated)
Information provided by:
AstraZeneca Identifier:
First received: September 28, 2005
Last updated: August 29, 2011
Last verified: August 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2006
  Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)